Vironexis Biotherapeutics Revenue and Competitors

USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Vironexis Biotherapeutics's estimated annual revenue is currently $1.6M per year.(i)
  • Vironexis Biotherapeutics's estimated revenue per employee is $155,000

Employee Data

  • Vironexis Biotherapeutics has 10 Employees.(i)
  • Vironexis Biotherapeutics grew their employee count by 43% last year.

Vironexis Biotherapeutics's People

NameTitleEmail/Phone
1
CEO and Co-FounderReveal Email/Phone
2
Co-Founder & Board MemberReveal Email/Phone
3
Chief Development OfficerReveal Email/Phone
4
Operations ManagerReveal Email/Phone
5
Senior Staff ScientistReveal Email/Phone
6
Research AssociateReveal Email/Phone
7
Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$9.1M59-9%N/AN/A
#10
$16.6M1073%N/AN/A
Add Company

What Is Vironexis Biotherapeutics?

Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$1.6M

Revenue (est)

43%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.2M10-37%N/A
#2
$1.2M10-41%N/A
#3
$0.9M10N/AN/A
#4
$1.5M10N/AN/A
#5
$0.9M10N/AN/A